参莲胶囊配合介入疗法治疗继发性肝癌的临床观察

Clinical Observation of the Secondary Carcinoma Liver Cases Treated by Shenlian Capsule and Invasive Therapy

以肝动脉插管化疗、栓塞治疗69例具有血瘀证症状的继发性肝癌患者．其中32例（治疗组）加服参莲胶囊1个疗程以上。结果治疗组肝区疼痛、腹胀、烦躁、苔黄根腻等血瘀证症状改善，与对照组比较均P＜0．05；治疗组生活质量提高，用Karuafsky计分制统计．80～70分的明显较多（P＜0．05）；介入治疗后的毒副反应和并发症与对照组比较也有所减轻。因此参莲胶囊配合介入疗法不失为治疗具有血瘀证症状的继发性肝癌的有效方法，同时对控制原发性癌灶也有良好的作用。

Sixty-nine patients with secondary carcinoma of liver were treated by hepatic arterial catheterization and embolization methods,and 32 patients of them took Shenlian capsule Simultaneously. After one course of treatment such symptoms as the abdominal fullness,hepatalgia and so on were obviously improved. Toxic and side effects Induced by invasive therapy were markedly lowered with living quality increased in Shenlian capsule group. According to the Karuafsky counting the value in Shenlian capsule group (80～70)was higher than that in the control group (P<0.05),which suggesled that the invaslve thcropy plus Shenlian capsule for treatment of the patients with secondary carcinoma of blood stasis arc superior in many respects ic only using invasive therapy and are also cffective for controlling their primary carcinoma.